DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment


Molecular Imaging Homepage

Phase I trial demonstrates safe use of radiotracer produced in minutes Manufactured using a Ga-68 generator and a cold kit vial

Bracco Imaging acquires SurgVision Enables development of a real-time fluorescence image-guided surgery platform

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

Two new imaging agents may help physicians make better and quicker treatment decisions Could determine therapy response in 24 hours

Researchers develop targeted alpha therapy protocol for prostate cancer Determines most effective therapy with the least number of side effects

Eyeing theranostics, Sofie Biosciences completes acquisition of Zevacor Pharma Growth of FDG also influenced decision

Blue Earth Diagnostics partners with GE to manufacture Axumin PET agent in UK Agreements were made in other European countries

RefleXion Medical selects MedCrypt to secure its new radiotherapy technology Updated FDA guidelines put cybersecurity at forefront

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

Philips introduces its CardioMD IV SPECT system at ASNC meeting Smaller footprint and lower cost of ownership

Whole brain imaging of a
monkey's brain with ischemia
After injecting PEG-IONCs (b)
the details become clearer

Researchers in South Korea develop a new iron oxide-based MR contrast agent

by Lauren Dubinsky , Senior Reporter
The industry has made yet another breakthrough in the quest to find an alternative to gadolinium-based contrast agents.

Researchers at the Institute for Basic Science in South Korea developed a nontoxic contrast agent for MR and MR angiography that may be superior to gadolinium.

Story Continues Below Advertisement

Because patient safety is the priority

Metrasens is the name top hospitals trust! Click to see how Ferroguard stops threats before Zone 4, or call 630-541-6509

"Current clinically-used gadolinium-based contrast agents have intrinsic toxicity limitations, including nephrogenic systemic fibrosis from leached free Gd3+ ions in patients with renal function impairment, and gadolinium accumulation in the brain as well as skeletal system," Taeghwan Hyeon, director of the Center for Nanoparticle Research within IBS, told HCB News.

Contrast agents based on iron oxide nanoparticles are typically not used because the results they generate can be difficult to read. It's easy to see gadolinium since it appears white, but distinguishing iron oxide from air, hemorrhage, calcification, metal deposition and blood clots can be a challenge.

For instance, when imaging a patient with Alzheimer's disease, iron oxide in the blood vessels appears black and the amyloid plaques show up gray. That makes it hard to recognize the plaques from the background.

This occurs because gadolinium is a T1-type contrast agent and current iron oxide contrast agents are T2. But the research team at IBS did something new, and created ultrasmall T1 iron oxide nanoparticles called PEG-IONCs.

"Small-sized iron oxide nanoparticles exhibit good paramagnetic property, which is a required property for T1 positive MR contrast agents, and they showed good T1 MR performance," said Hyeon.

They tested the PEG-IONCs on large animals, including rabbits, beagles, and macaque monkeys. Experiments could not be done on mice because the results wouldn't directly translate to humans.

Hematological and tissue compatibility studies in macaque monkeys demonstrated that PEG-IONCs are highly biocompatible. Current iron oxide contrast agents have to be slowly infused to reduce the risk of hypotension and other serious side effects, but PEG-IONCs can be administered without trouble.

The research team then conducted more challenging dynamic imaging on dogs and monkeys to see the vascular flow patterns of cerebral ischemia, which causes stroke.

Images were captured every 1.5 seconds after the PEG-IONCs were injected in order to see the blood perfusion patterns in the brain. The team was successful in detecting an occlusion in the middle cerebral artery.

"Extensive uses and eventual replacement [largely] depend on how serious the toxicity issues of currently clinically-used gadolinium-based contrast agents are," said Hyeon. "But at least PEG-IONCs will replace some applications of gadolinium-based contrast agents, including diagnosis of stroke and other brain diseases such as tumors, in which vascular and perfusion MR imaging are clinically important."

But he cautions that more rigorous preclinical and clinical evaluations are needed to confirm this.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2017, Inc.